Kidney Neoplasms
Recent clinical, regulatory, research and industry developments relating to this disease.
Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma (ccRCC).
PD-1 immunology in the kidneys: a growing relationship.
Renal Cell Carcinoma: A Review.
Saturation genome editing maps the functional spectrum of pathogenic VHL alleles.
Applications of artificial intelligence in urologic oncology.
Geographic variation of mutagenic exposures in kidney cancer genomes.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q4 2026.
- Active recent publication activity, including 2 notable findings.
Research HighlightsViewHide
- 2026-01-28Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial.Fernandes R · 2026
- 2026-01-28Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial.Porcari S · 2026
Clinical MilestonesViewHide
- 2026-06-08Academic-Industrial Partnership for Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) ImagingResults expected Q4 2028
- 2025-12-31A Study of the Clinical Application of [18F]RCCB6 PET/ CT Imaging in the Diagnosis of Kidney CancerResults expected Q4 2026
- 2026-06-08ClinicalAcademic-Industrial Partnership for Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) ImagingResults expected Q4 2028
- 2026-04-14ClinicalA Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)Results posted
- 2026-01-28ResearchFecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial.Fernandes R · 2026
- 2026-01-28ResearchFecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial.Porcari S · 2026
- 2025-12-31ClinicalA Study of the Clinical Application of [18F]RCCB6 PET/ CT Imaging in the Diagnosis of Kidney CancerResults expected Q4 2026
- 2025-09-04ClinicalA Phase 2 Trial to Evaluate the Safety and Efficacy of NKT2152 in Combination With Palbociclib (Doublet) and With Palbociclib and Sasanlimab (Triplet) in Subjects With Advanced or Metastatic Clear Cell Renal Cell CarcinomaTerminated
Research-associated treatments
Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Kidney Neoplasms27
- Carcinoma, Renal Cell25
- Lung Neoplasms4
- Antineoplastic Combined Chemotherapy Protocols3
- Carcinoma, Non-Small-Cell Lung3
- Melanoma3
- Carcinoma, Transitional Cell2
- Fecal Microbiota Transplantation2
Leading journals6
- The New England journal of medicine10
- Journal for immunotherapy of cancer3
- Nature medicine3
- Cancer treatment reviews2
- ESMO open2
- International journal of molecular sciences2
Leading researchers8
- Choueiri TK12
- Motzer RJ11
- Powles T7
- Rini BI7
- Tannir NM7
- Donskov F6
- Escudier B6
- Gurney H6
Affiliations (unnormalised)6
- Dana-Farber Cancer Institute6
- Memorial Sloan Kettering Cancer Center5
- The University of Texas MD Anderson Cancer Center5
- Beth Israel Deaconess Medical Center4
- Lank Center for Genitourinary Oncology3
- Memorial Sloan-Kettering Cancer Center3
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Kidney neoplasms are tumors or cancers arising in the kidney. The supplied literature focuses mainly on renal cell carcinoma, including localized and advanced disease, with attention to screening, diagnosis, staging, treatment, and management.
Clear cell renal cell carcinoma, the most common histologic subtype, is characterized by inactivation of the von Hippel-Lindau tumor suppressor gene. The grounding also links kidney cancer biology to the tumor microenvironment, immune mechanisms, and complement system dysregulation as contributors to tumorigenesis.
The supplied grounding does not support specific risk factors for kidney neoplasms. It does note that tumor histology and risk stratification are important for treatment selection, but not for disease risk.
Management includes surgery for localized disease and, for relapsed or stage IV renal cell carcinoma, surgery and/or systemic therapy. Systemic treatment categories in the grounding include targeted therapy agents such as VEGF- and mTOR-directed drugs, as well as immune checkpoint inhibitors and IL-2-based immunotherapy.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Tumors or cancers of the KIDNEY.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.